

Benefiting



Mass General Brigham
Neuroscience Institute



The Josephine and John Marr
Alzheimer's Research Fund

HELP END ALZHEIMER'S DISEASE

Thanks to the Marr Fund, we are accelerating prevention, treatment, and cures for Alzheimer's disease.

The Marr Fund:

- Helped confirm that the abnormalities responsible for Alzheimer's begin decades before clinical symptoms
- Served as a catalyst for securing millions of dollars in federal funding and private philanthropy, most notably, a matching gift from the GHR Foundation for a prevention study
- Most recently, fueled research to better understand what makes some people resilient to Alzheimer's and to identify biological pathways in the brain that could lead to prevention



For the Marr Fund Team, our run is more than a race. It's a tribute to a wonderful family, a celebration of resilience, and an investment in hope. Every dollar we raise and every mile we run helps advance better treatments and outcomes for people with Alzheimer's."

(Left to right) **Shaun Collins, Cary Gemmer Blake, Craig Blake**
Marr Fund Supporters

RUN WITH THE MARR FUND TEAM



October 4, 2026

Participate in the Maine Marathon, Half Marathon, Relay, or virtual event on October 4, and raise vital funds to support Alzheimer's prevention research.

LEARN MORE



For questions, contact
mainemarathon@mgb.org



2024: The FDA approves a second disease-modifying therapy for early stages of Alzheimer's.

2025: During an uncertain funding climate, the Marr Fund steps up to ensure early-stage Alzheimer's research continues to move forward.



The Marrs

2022: The Marr Fund begins to support research on genetic pathways in Alzheimer's and Alzheimer's resiliency.

2023: The FDA grants full approval for the first disease-modifying treatment for Alzheimer's, now used worldwide.



route 88

2016: An early clinical trial shows the first encouraging results in decades for an Alzheimer's treatment.

2020: Enrollment begins for two global Alzheimer's prevention trials, which include people as young as age 55.



Recent Developments in Alzheimer's Disease Research